“As our private equity clients around the world continue to pursue innovation-fueled opportunities, we are delighted Matt is joining our global team,” said Michael Kendall, co-chair of Goodwin’s Private Equity practice. “Matt is an incredibly talented lawyer, and his experience with buyouts, M&A, and portfolio company transactions and advisory is closely aligned with our clients’ needs.”
Gruenberg’s practice focuses on a wide array of complex corporate transactions, including mergers and acquisitions, buyouts, restructurings, and control and non-control equity investments. He has advised on domestic and cross-border transactions across multiple industries, including technology, financial services, healthcare, manufacturing, and consumer retail. He represents private equity sponsors and their portfolio companies throughout the lifecycle of their investments, from acquisitions to ongoing management through to liquidity events. Gruenberg has been listed in New York Super Lawyers as a “Rising Star” for mergers and acquisitions.
“I am very excited to join Goodwin,” said Gruenberg. “The firm’s transactional practice is best in class and widely respected in the legal and business communities. As a market leader in M&A, private equity, and venture capital, Goodwin has built an incredible global platform. I look forward to working with the team and delivering exceptional service to our clients.”
Goodwin’s global Private Equity practice has grown substantially in the last 12 months, with the arrival of Edwin Chan in Hong Kong; Jan Schinkoth in Germany; Josh Ratner and Pavel Shaitanoff in New York; and James Grimwood, Erik Dahl, Christian Iwasko, Sava Savov, Michelle Tong, John Van De North, Geoff O’Dea, Hugh O’Sullivan, and Dulcie Daly in London. Goodwin now has more than 300 private equity lawyers in the US, Europe, and Hong Kong.
Refinitiv named Goodwin the number one firm for private equity and venture capital rounds, and the number one legal advisor (by deal count) for global and U.S. M&A in Q1 2021. Mergermarket’s latest Deal Drivers reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America; the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa; and the number three firm (by deal count) for Tech, Media, and Telecoms M&A in North America. Goodwin was recently ranked highly for private equity in Chambers and Legal 500.